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This study investigated the maximum tolerated dose of S-1 based on the frequency of its dose-limiting toxicities (DLT) with
concurrent radiotherapy in patients with locally advanced pancreatic cancer. S-1 was administered orally at escalating doses from 50
to 80mgm
 2 b.i.d. on the day of irradiation during radiotherapy. Radiation therapy was delivered through four fields as a total dose of
50.4Gy in 28 fractions over 5.5 weeks, and no prophylactic nodal irradiation was given. Twenty-one patients (50 three; 60 five; 70 six;
80mgm
 2 seven patients) were enrolled in this trial. At a dose of 70mgm
 2 S-1, two of six patients demonstrated DLT involving
grade 3 nausea and vomiting and grade 3 haemorrhagic gastritis, whereas no patients at doses other than 70mgm
 2 demonstrated
any sign of DLT. Among the 21 enrolled patients, four (19.0%) showed a partial response. The median progression-free survival time
and median survival time for the patients overall were 8.9 and 11.0 months, respectively. The recommended dose of S-1 therapy with
concurrent radiotherapy is 80mgm
 2day
 1. A multi-institutional phase II trial of this regimen in patients with locally advanced
pancreatic cancer is now underway.
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Pancreatic cancer (PC) is one of the leading causes of cancer death
worldwide. The prognosis of patients with this disease remains
extremely poor, with a 5-year survival rate after diagnosis of less
than 5%. Despite recent improvements in diagnostic techniques,
PC is diagnosed at an advanced stage in most patients. Among
these patients, roughly one-third is diagnosed as having locally
advanced disease radiographically confined to the pancreas and
surrounding tissues. In patients with locally advanced PC, the
concurrent external-beam radiation therapy and 5-fluorouracil
(5-FU) therapy has been shown to offer a survival benefit in
comparison with radiotherapy alone (Moertel et al, 1969, 1981) or
chemotherapy alone (Gastrointestinal Tumor Study Group, 1988).
In an attempt to improve the efficacy of 5-FU with concurrent
radiotherapy, various anticancer agents and radiation schedules
are being examined in clinical trials, but no significant impact on
survival has been accomplished. Because of these results, 5-FU
with concurrent radiotherapy remains the predominant chemor-
adiotherapy for locally advanced PC in clinical use (Willett et al,
2005; Yip et al, 2006).
S-1 is a novel orally administered drug, which is a combination
of tegafur, 5-chloro-2,4-dihydroxypyridine and oteracil potassium
in a 1:0.4:1 molar concentration ratio. Tegafur is hydroxylated
and converted to 5-FU by the hepatic microsomal enzymes.
5-Chloro-2,4-dihydroxypyridine is a competitive inhibitor of
dihydropyrimidine dehydrogenase, which is involved in the
degradation of 5-FU, and acts to maintain effective concentrations
of 5-FU in plasma and tumour tissues. Oteracil potassium, a
competitive inhibitor of orotate phosphoribosyltransferase, in-
hibits the phosphorylation of 5-FU in the gastrointestinal tract,
reducing the serious gastrointestinal toxicity associated with 5-FU
(Shirasaka et al, 1996a). In athymic nude rats, S-1 has been shown
to result in retention of a higher and more prolonged concentra-
tion of 5-FU in plasma and tumour tissues in comparison with 5-
FU and uracil/tegafur (Shirasaka et al, 1996b). The antitumour
effect of S-1 has already been demonstrated in a variety of solid
tumours, including advanced gastric cancer (Sakata et al, 1998),
colorectal cancer (Ohtsu et al, 2000), non-small-cell lung cancer
(Kawahara et al, 2001), and head and neck cancer (Inuyama et al,
2001). In patients with metastatic PC, a recent early phase II study
has demonstrated a response rate of 21% (Ueno et al, 2005), and a
more favourable tumour response (response rate: 38%) and
survival (median: 8.8 months) have been reported in a multi-
institutional late phase II trial of S-1 (Furuse et al, 2005).
Thus, S-1 has promising antitumour activity against advanced
PC, and is much more convenient to administer than intravenous
5-FU infusion, as it is taken orally. Concurrent radiotherapy along
with S-1 therapy as an alternative to 5-FU infusion may result in
more efficient treatment and improve the quality of life of patients.
Therefore, we conducted a phase I trial to determine the maximum
tolerated dose of S-1 with concurrent radiotherapy based on the
frequency of dose-limiting toxicities (DLT) in patients with locally
advanced PC.
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sPATIENTS AND METHODS
Eligibility
Patients eligible for study entry had histologically or cytologically
confirmed locally advanced nonresectable PC. Eligibility criteria
were age 20–74 years; Karnofsky performance status 70–100
points; no evidence of distant metastasis; adequate oral intake;
estimated life expectancy X12 weeks after study entry; no earlier
treatment for PC; adequate haematological function (haemoglobin
X10gdl
 1,l e u c o c y t e sX4000mm
 3, neutrophils X2000mm
 3 and
platelets X100000mm
 3); adequate hepatic function (serum total
bilirubin p2.0 times upper normal limit (UNL); serum albumin
X3.0gdl
 1 and serum transaminases (aspartate aminotransferase
(AST)/alanine aminotransferase (ALT)) p2.5 times UNL or p5
times UNL if biliary drainage present); adequate renal function
(serum creatinine p1.0mgdl
 1); written informed consent.
The exclusion criteria were watery diarrhoea; pleural effusion or
ascites; active infection; active gastroduodenal ulcer; severe
complication such as heart disease or renal disease; mental
disorder; history of drug hypersensitivity; active concomitant
malignancy; pregnant and lactating females; females of child-
bearing age unless using effective contraception.
Ultrasonography, multidetector row-computed tomography of
the abdomen and chest X-ray were performed for pretreatment
staging to assess the local extension of the tumour and exclude the
presence of distant metastasis. The computed tomography-based
criteria for tumour nonresectability included tumour encasement
of the celiac trunk, common hepatic artery, superior mesenteric
artery or bilateral invasion of the portal vein. All patients with
obstructive jaundice underwent percutaneous transhepatic or
endoscopic retrograde biliary drainage before treatment. This
phase I study was approved by the Institutional Review Board of
the National Cancer Center and conducted in accordance with the
Declaration of Helsinki Principles.
Treatment schedule
This was an open-label, two-institutional and single-arm phase I
study that was performed on an in-patient basis. Radiotherapy was
administered by 10 or 25MV photons using three-dimensional
treatment planning. A total dose of 50.4Gy was delivered in 28
fractions over 5.5 weeks. The clinical target volume (CTV)
included only the gross primary tumour and nodal involvement
enlarged over 10mm detected by computed tomography. Elective
nodal irradiation was not used. The planning target volume was
defined as CTV plus a 10mm margin in the lateral direction and
10–20mm margin in the craniocaudal direction to account for
respiratory organ motion and daily set-up error. The four-field
technique (anterior, posterior and opposed lateral fields) was used.
There was no field reduction. The spinal cord dose was maintained
below 45Gy. The dose received by X50% of the liver was limited
to p30Gy, and that received by X50% of both kidneys was
limited to p20Gy.
S-1 was administered orally twice daily after breakfast and
dinner on the day of irradiation (Monday to Friday) during
radiotherapy. The initial dose of S-1 was 50mgm
 2day
 1, and the
dose was escalated to 80mgm
 2day
 1 in increments of
10mgm
 2day
 1 (Table 1). The calculated S-1 dose was rounded
down to the nearest 60, 80, 100 or 120mg. S-1 at 50mgm
 2day
 1
is reported to be almost equivalent to 200mgm
 2day
 1 intrave-
nously 5-FU (Hirata et al, 1999), which has been used in protracted
5-FU infusion with concurrent radiotherapy for locally advanced
PC at our institutions (Ishii et al 1997). S-1 at 80mgm
 2day
 1 is
the standard dose used as a single agent for systemic therapy
(Furuse et al, 2005; Ueno et al, 2005). Patients maintained a daily
journal to record their intake of S-1 and any signs or symptoms
that they experienced.
Patient cohorts had a minimum of three patients at each dose
level. If no DLT was observed in the initial three patients, the
dosage was escalated in successive cohorts. If DLT was observed in
one or two of the initial three patients, three additional patients
were evaluated at that dose level. If only one or two of six patients
experienced DLT, dose escalation was continued. However, if three
or more patients experienced DLT at a given dose level, then the
previous dose level was considered as the maximum tolerated
dose. Dose-limiting toxicities was defined as the following
manifestations of toxicity observed until completion of chemo-
radiotherapy: grade 3 leucocytopenia and/or neutropenia with a
fever X381C lasting 3 days or more, grade 3 leucocytopenia and/or
neutropenia with infection, grade 4 leucocytopenia and/or
neutropenia lasting 3 days or more, grade 4 leucocytopenia and/
or neutropenia requiring haematopoietic colony-stimulating fac-
tors, platelets o25000mm
 3, grade 3 thrombocytopenia requiring
transfusion, serum AST/ALT X10 times UNL, grade 3 or 4
nonhaematological toxicities excluding nausea, vomiting, anorex-
ia, fatigue, constipation, hyperglycaemia, and abnormality of
sodium, potassium, and calcium or treatment interruption for
longer than 12 days.
When grade 3 or greater haematological toxicity, total bilirubin
level 2.0–3.0 times UNL, serum AST/ALT 5.0–10.0 times UNL,
grade 3 vomiting and/or grade 2 nonhaematological toxicity
excluding nausea, vomiting, anorexia, fatigue, constipation,
alopecia and pigmentation change, were observed, radiotherapy
and S-1 administration was suspended. Treatment was resumed
when the toxicities were resolved by one grade or more, compared
with these suspension criteria. Dose modification was not
performed in this study. When DLT or tumour progression was
observed during chemoradiotherapy, this treatment was discon-
tinued. After this treatment, the patients were allowed to receive
another anticancer treatment at their physician’s discretion.
Toxicity and response evaluation
The primary end point of this trial was to evaluate the frequency of
DLT, and the secondary end point was to evaluate the potential
antitumour activity. Treatment-related toxicities were assessed
using the National Cancer Institute Common Toxicity Criteria
version 2.0. During this treatment, complete blood count with
differentials, serum chemistry and urinalysis were carried out at
least once a week. Tumor response was evaluated at the completion
of chemoradiotherapy and every 8 weeks thereafter until tumour
progression, according to the Japan Society for Cancer Therapy
criteria (Japan Society for Cancer Therapy, 1993) as follows: a
complete response was defined as the disappearance of all clinical
evidence of the tumour for a minimum of 4 weeks. A partial
response was defined as a 50% or greater reduction in the sum of
the products of two perpendicular diameters of all measurable
lesions for a minimum of 4 weeks. A minor response was defined
as a 25% or greater reduction and less than 50% in the sum of the
products of two perpendicular diameters of all measurable lesions
for a minimum of 4 weeks or a 50% or greater reduction in the
sum of the products of two perpendicular diameters of all
measurable lesions lasting less than 4 weeks. No change was
defined as a reduction of less than 25% or a less than 25% increase
Table 1 Dose schedules of S-1 with concurrent radiotherapy
Dosage level S-1 dose (mgm
 2day
 1) Number of patients
15 0 3
26 0 5
37 0 6
48 0 7
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sin the sum of the products of two perpendicular diameters of all
lesions for a minimum of 4 weeks. Progressive disease was defined
as an increase of 25% or more in the sum of the products of two
perpendicular diameters of all lesions, or the appearance of any
new lesion. Progression-free survival time was defined as the time
from the date of initial treatment to the first documentation of
progression or death. Overall survival was measured from the date
of initial treatment to date of death or the date of the last follow-
up. Progression-free and overall survival times were calculated by
the Kaplan–Meier method. Serum carcinoembryonic antigen
(CEA) levels and serum carbohydrate antigen 19-9 (CA19-9) levels
were measured at least every 8 weeks by a radioimmunometric
assay using the Centocor radioimmunoassay kit (Centocor Inc.,
Malvern, PA, USA).
RESULTS
Patient characteristics
Twenty-one patients were enrolled in this study from May 2004
and November 2005 at the National Cancer Center Hospital,
Tokyo, and the National Cancer Center Hospital East, Kashiwa,
Chiba, Japan. The characteristics of the patients are listed in
Table 2. The median age was 59 years (range: 51–74). Karnofsky
performance status was 100 in 12 patients (57%), 90 in 8 (38%) and
80 in one (5%). The median maximum tumour size was 37mm
(range: 25–60), and the median planning target volume was
265cm
3 (range: 153–408). The causes of the unresectable PCs were
invasion of the celiac trunk in nine patients, invasion of the
superior mesenteric artery in eight patients and invasion of both
regions in four patients. Patients were treated with S-1 and
concurrent radiation over four dose levels, as listed in Table 1.
After completion of chemoradiotherapy, 20 patients (95%)
received gemcitabine alone for their cancer until disease progres-
sion, and one patient received the other treatment at another
hospital.
Toxicity
The toxicities observed in the 21 enrolled patients are listed in
Table 3. With regard to overall haematological toxicity, grade 3
neutropenia was observed in only one patient at the dose of level 1,
and other grades 3–4 toxicities were not observed. For non-
haematological toxicity, grade 3 anorexia and nausea (three
patients), grade 3 vomiting (one patient) and grade 3 haemo-
rrhagic gastritis (one patient) occurred at level 3, and grade 3 AST
elevation was observed in a patient at level 4. As a late toxicity,
duodenal ulcer with epigastralgia was observed in one patient at
level 3 (S-1 70mgm
 2) 8 months after chemoradiotherapy,
requiring embolisation of the gastroduodenal artery to treat severe
bleeding from the ulcer and a 2-month hospital stay. No other
grades 3–4 nonhaematological toxicities or treatment-related
deaths occurred in this study. Treatment was suspended in four
patients (level 2, one; level 3, two; level 4, one patient) because of
obstructive jaundice (two patients) or grade 3 anorexia (two
patients); the durations of S-1 dose withholding were 3, 12, 2 and
13 days, respectively. One patient with grade 3 anorexia (level 3)
was unable to resume this treatment. The compliance rate of the
patients taking S-1 was as high as 99% (1170/1176 doses).
There was no occurrence of DLT at the dose of levels 1 or 2, but
two of six patients who received a level 3 dose experienced DLT;
one of these patients required suspension of treatment for more
than 12 days due to grade 3 anorexia, nausea and vomiting after the
third fraction of chemoradiotherapy, and a second developed grade
3 haemorrhagic gastritis after completion of 13 fractions. However,
no DLT at a dose of level 4 was observed, and S-1 at 80mgm
 2 with
concurrent radiotherapy was considered to be well-tolerated.
Five patients (level 2, two; level 3, two; level 4, one) of the 21 who
were enrolled had to abandon this treatment. Two patients at level
2 developed massive ascites and infarction of the cerebellum,
respectively, during chemoradiotherapy. The cause of the massive
ascites was disease progression, as cancer cells were confirmed in
the ascitic fluid. The cerebellar infarction was considered to have
been unrelated to the treatment, because the patient had a history
of the same problem. Two patients at level 3 had to discontinue the
treatment because of DLT according to the protocol, and one
patient at level 4 decided to stop the treatment, despite lack of
severe toxicity, at her own request.
Efficacy
All the patients were included in the response evaluation. Four
patients (levels 1 and 2, 0; level 3, one; level 4, three) achieved a
partial response, giving an overall response rate of 19% (95%
confidence interval, 5–42%). Four patients (19%) showed a minor
response, and nine (43%) and three patients (14%) had no change
and progressive disease, respectively. Tumor response could not be
evaluated in one patient (5%), because she was transferred to
another hospital to seek some other treatment for her PC. None of
the patients’ conditions improved to resectable or operable
diseases after the completion of treatment. After the start of
chemoradiotherapy, the serum CA19-9 level was reduced by more
than 50% compared to the pretreatment level in 14 (88%) of 16
patients who had shown a pretreatment level of 100U/ml or
greater, and the serum CEA level was reduced by more than 50%
relative to the pretreatment level in three (100%) of three patients
who had a pretreatment level of 10ngml
 1 or greater. Eighteen of
the 21 patients had disease progression at the time of analysis. The
pattern of disease progression was distant metastases in 11 (52%),
deterioration of general condition in five (24%) and locoregional
recurrence in two patients (10%). The median progression-free
survival time for all patients was 8.9 months (Figure 1). At the time
of analysis, 13 patients had died due to tumour progression. The
median survival time and 1-year survival rate for patients as a
whole were 11.0 months and 42.9%, respectively (Figure 1).
Table 2 Patient characteristics
Characteristics Number of patients %
Age (years)
Median 59
Range 51–74
Gender
Male 9 43
Female 12 57
Karnofsky performance status
100 12 57
90 8 38
80 1 5
Tumour location
Head 13 62
Body-tail 8 38
Maximum tumour size (mm)
Median 37
Range 25–60
CEA (ng/ml)
Median 4.5
Range 1.0–75.0
CA19-9 (U/ml)
Median 759
Range 1–6,300
CEA¼carcinoembryonic antigen; CA19–9¼carbohydrate antigen 19–9.
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sDISCUSSION
On the basis of results of previous randomised controlled
trials (Moertel et al, 1969, 1981; Gastrointestinal Tumor Study
Group, 1988), the combination of 5-FU therapy and radiotherapy
has become a frequently employed treatment for locally advanced
PC (Willett et al, 2005; Yip et al, 2006). Because of the modest
survival benefit of 5-FU-based chemoradiotherapy, numerous
investigators are pursuing phase I and II trials of radiotherapy
with new chemotherapeutic agents such as gemcitabine, paclitaxel,
capecitabine, bevacizumab, gefitinib and erlotinib (Blackstock
et al, 2003; Okusaka et al, 2004; Rich et al, 2004; Crane et al,
2006; Czito et al, 2006). However, no marked improvement of
survival has been observed. S-1 is an oral fluoropyrimidine
derivative that has demonstrated excellent efficacy with mild
toxicity in patients with metastatic PC (Furuse et al, 2005). It is
considered to be beneficial because of its convenience of being
administered by the oral route. In addition, combined S-1 and
radiotherapy has been demonstrated to exert a synergistic effect
against 5-FU-resistant cancer xenografts (Harada et al, 2004;
Nakata et al, 2006). Therefore, a clinical trial of concurrent
radiotherapy with S-1 therapy for locally advanced PC was
designed to intensify the treatment efficacy and improve the
convenience of administration.
In this study, a limited radiation field, of which the planning
target volume included only the gross tumour volume without
prophylactic nodal irradiation, was adopted to minimise the
volume of normal tissue treated, because our retrospective study
showed that a larger planning target volume for irradiation was the
significant predictor of severe acute gastrointestinal toxicity in
patients treated with chemoradiotherapy (Ito et al, 2006). A similar
radiation field has been attempted in recent reported trials of
chemoradiotherapy to decrease the degree of gastrointestinal
toxicity (Muler et al, 2004; Crane et al, 2006). Gastrointestinal
toxicities, such as anorexia, nausea and vomiting, are major
troublesome adverse events during chemoradiotherapy, necessi-
tating intravenous fluid infusion and sometimes discontinuation of
chemoradiotherapy (Talamonti et al, 2000; Crane et al, 2002;
McGinn and Zalupski, 2003; Okusaka et al, 2004). In the present
study, some gastrointestinal toxicities were observed, but were
easily managed. Moreover, the limited radiation field used in this
study did not result in excess failures in the border of radiation
field, because locoregional recurrence was observed in only two
patients of this series.
In this study, DLT was observed in only two patients at level 3
(S-1 70mgm
 2). The DLT in the first patient was grade 3 anorexia,
nausea and vomiting, requiring suspension of treatment for longer
than 12 days, and the second DLT was grade 3 haemorrhagic
gastritis. Other than DLT toxicity, acute grades 3–4 toxicities
during chemoradiotherapy were observed in only three patients:
grade 3 neutropenia, grade 3 anorexia and nausea, and grade 3
AST elevation in one patient each. As a late toxicity, duodenal
ulcer was observed 8 months after treatment in one patient at level
3, but no other late toxicity occurred. Accordingly, S-1 at a daily
dose of 80mgm
 2 (level 4) was considered to be well tolerated,
and this dose was deemed recommendable.
In patients with locally advanced PC who are receiving
chemoradiotherapy, it is important to enhance local control while
simultaneously reducing the risk of distant metastases. In
concurrent gemcitabine-based chemoradiotherapy, both full-dose
gemcitabine and standard-dose radiotherapy are difficult to
administer because of their associated toxicities (Crane et al,
2002; Blackstock et al, 2003; McGinn and Zalupski, 2003; Okusaka
Table 3 Toxicity
Number of patients
Level 1 (n¼3) Level 2 (n¼5) Level 3 (n¼6) Level 4 (n¼7)
Grade 1,2 3 4 1,2 3 4 1,2 3 4 1,2 3 4
Leucocytes 3 0 0 3 0 0 3 0 0 6 0 0
Neutrophiles 1 1 0 1 0 0 2 0 0 3 0 0
Haemoglobin 0 0 0 2 0 0 1 0 0 4 0 0
Platelets 0 0 0 1 0 0 1 0 0 2 0 0
Anorexia 2 0 0 3 0 0 1 3 0 5 0 0
Nausea 0 0 0 2 0 0 1 3 0 6 0 0
Vomiting 1 0 0 0 0 0 2 1 0 3 0 0
Diarrhoea 1 0 0 0 0 0 0 0 0 0 0 0
Mucositis 0 0 0 0 0 0 0 0 0 0 0 0
Fatigue 2 0 0 2 0 0 2 0 0 2 0 0
Gastritis 0 0 0 0 0 0 0 1 0 0 0 0
Duodenal ulcer 0 0 0 0 0 0 0 1 0 0 0 0
Bilirubin 1 0 0 0 0 0 0 0 0 0 0 0
Hypoalbuminaemia 1 0 0 1 0 0 3 0 0 5 0 0
A S T 100 100 400 200
A L T 100 000 300 110
Alkaline phosphatase 0 0 0 0 0 0 1 0 0 2 0 0
Creatinine 0 0 0 0 0 0 1 0 0 0 0 0
AST¼aspartate aminotransferase; ALT¼alanine aminotransferase.
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Figure 1 Overall survival and progression-free survival curves of 21
patients who received S-1 with concurrent radiotherapy for locally
advanced pancreatic cancer. Tick marks indicate censored cases.
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set al, 2004). In contrast, in the present trial, the combination of
full-dose S-1 (80mgm
 2) and standard-dose radiotherapy
(50.4Gy/28 fractions) was easy to administer and had favourable
toxicity profiles. Therefore, this regimen might have a dual benefit
of counteracting systemic tumour spread as well as acting as a
potent radiosensitizer for local control. With regard to the
antitumour activity of this treatment, four (19%) of the 21 patients
achieved a partial response, and the response rate at the
recommended dose was 43% (3/7). The progression-free survival
time (median: 8.9 months) and overall survival time (median: 11.0
months) were also favourable as a phase I trial. In this study, many
patients (95%) received gemcitabine alone after completion of this
regimen. Such adjuvant gemcitabine therapy might influence the
efficacy of treatment, although the extent of its impact on tumour
response and survival has not been fully elucidated in patients with
locally advanced PC. Since both the efficacy and toxicity profile of
this regimen appear to be attractive, a phase II trial is required to
clarify the antitumour activity, survival and toxicity of S-1
80mgm
 2day
 1 with concurrent radiation therapy for locally
advanced PC.
In conclusion, the recommended dose of S-1 with concurrent
radiotherapy is 80mgm
 2day
 1 on the day of irradiation, and this
regimen has a mild toxicity profile while delivering substantial
antitumour activity for patients with locally advanced PC. Orally
administered S-1 may offer an easy alternative to intravenous 5-FU
without impairing the quality of life. A phase II trial of S-1 at the
optimal dose of 80mgm
 2day
 1 with concurrent radiation in
patients with locally advanced PC is now underway in a multi-
institutional setting.
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